Yenna Lee et al.’s study demonstrated that PPARα agonists can mitigate the progression of atherosclerosis and the exacerbation of hepatic steatosis in Apoe−/−FXR−/− mice by promoting beta-oxidation, fatty acid uptake, and triglyceride hydrolysis [59]. Here, PPARA is linked to Hepatic steatosis.